Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Gene Ther. 2012 Mar 8;20(2):158–168. doi: 10.1038/gt.2012.16

Figure 2.

Figure 2

Cell viability and transduction efficiency with AAV-GFP serotypes 2, 3, and 6 using rMAPC 3D culture system. Percentage of viable undifferentiated and osteogenically differentiated rMAPC (OD-MAPC) 72h after transduction with AAV-GFP serotype 2, 3, and 6 (a) when compared to untransduced cells (100%). Transduction efficiency after 72h in undifferentiated and differentiated MAPC measured by the percentage of cells expressing GFP vector (b). *p≤0.01, **p≤0.05, and #p=0.06, when statistically compared undifferentiated versus differentiated MAPC. Data are shown as mean ±SD of three independent experiments.